Edition:
United Kingdom

People: PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

45.19USD
8:07pm BST
Change (% chg)

$-2.00 (-4.24%)
Prev Close
$47.19
Open
$47.33
Day's High
$47.38
Day's Low
$45.01
Volume
118,994
Avg. Vol
347,775
52-wk High
$52.95
52-wk Low
$14.57

Peltz, Stuart 

Dr. Stuart W. Peltz, Ph.D. is a Chief Executive Officer, Director of PTC Therapeutics, Inc. Dr. Peltz is a co-founder of PTC Therapeutics, Inc., and has served as our Chief Executive Officer and a member of our Board since our inception in 1998. He also serves as a director of PTC Therapeutics International Limited, our international headquarters and indirect wholly-owned subsidiary, and as a director of one of our international subsidiary boards. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz previously served as a board member of the BioNJ Board of Trustees from 2005 to 2017, including as its Chairman from 2014 to 2016. Dr. Peltz has received a number of business and scientific awards, including election as a Fellow of the American Academy for the Advancement of Science in 2010, recipient of the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014 and recognition as PharmaVoice's 100 Most Inspiring People in 2009. He served as a member of the board of directors for the Biotechnology Industry Organization (BIO) from 2010 to 2015, including being on BIO's Emerging Companies Section Governing Board. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Basic Compensation

Total Annual Compensation, USD 938,897
Restricted Stock Award, USD 242,568
Long-Term Incentive Plans, USD --
All Other, USD 991,218
Fiscal Year Total, USD 2,172,680

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Schmertzler

242,177

Stuart Peltz

2,172,680

Christine Utter

870,741

Marcio Souza

1,524,270

Neil Almstead

951,918

Mark Boulding

1,121,910
As Of  31 Dec 2017